Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and tadalafil

lenalidomide has been researched along with tadalafil in 4 studies

Compound Research Comparison

Studies
(lenalidomide)		Trials
(lenalidomide)		Recent Studies (post-2010)
(lenalidomide)		Studies
(tadalafil)		Trials
(tadalafil)		Recent Studies (post-2010) (tadalafil)
3,5327252,8501,7423921,089

Protein Interaction Comparison

ProteinTaxonomylenalidomide (IC50)tadalafil (IC50)
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0012
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0012
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0012
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0012
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)3.0704
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit deltaHomo sapiens (human)2.928
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)3.0704
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.5153
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaBos taurus (cattle)5.1
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaBos taurus (cattle)4.05
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaHomo sapiens (human)2.928
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Bos taurus (cattle)5.1
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)2.928
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaBos taurus (cattle)5.1
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit betaBos taurus (cattle)5.1
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)9.2
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit betaHomo sapiens (human)2.928
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)2.507
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)3.0704
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.012
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)4.6028
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)9.2
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)4.6028
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)3.0704
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)2.928
cGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)0.0075
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit deltaBos taurus (cattle)5.1
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)0.8575
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)3.0704
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)3.0704

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Borrello, I; Bui, M; Ghosh, N; Noonan, KA; Rudraraju, L1
Hountras, P; Lane, T1

Reviews

1 review(s) available for lenalidomide and tadalafil

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for lenalidomide and tadalafil

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
    Cancer immunology research, 2014, Volume: 2, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Clarithromycin; Dexamethasone; Humans; Immune Tolerance; Immunologic Factors; Interleukin-4 Receptor alpha Subunit; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Phosphodiesterase 5 Inhibitors; T-Lymphocytes; Tadalafil; Thalidomide

2014
A 65-Year-Old Man With Weight Loss, Peripheral Neuropathy, and Lower Extremity Swelling.
    Chest, 2022, Volume: 161, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Edema; Exercise Tolerance; Humans; Hypertension, Pulmonary; Lenalidomide; Male; Neoplasms, Plasma Cell; Peripheral Nervous System Diseases; Phosphodiesterase 5 Inhibitors; POEMS Syndrome; Positron Emission Tomography Computed Tomography; Stem Cell Transplantation; Syncope; Tadalafil; Weight Loss

2022